The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).
 
Masaoki Ito
No Relationships to Disclose
 
Carles Codony-Servat
No Relationships to Disclose
 
Jordi Codony-Servat
No Relationships to Disclose
 
Ilaria Attili
No Relationships to Disclose
 
Laura Bonanno
No Relationships to Disclose
 
Matteo Fassan
No Relationships to Disclose
 
Jordi Berenguer
No Relationships to Disclose
 
Jillian Bracht
No Relationships to Disclose
 
Nuno Monteiro Gil
Consulting or Advisory Role - Bayer; Grunenthal
Travel, Accommodations, Expenses - Lilly; Lilly; Merck Sharp & Dohme; Pfizer
 
Morihito Okada
No Relationships to Disclose
 
Andres Felipe Cardona Zorrilla
No Relationships to Disclose
 
Niki Karachaliou
No Relationships to Disclose
 
David Jablons
No Relationships to Disclose
 
Peng Cao
No Relationships to Disclose
 
Rafael Rosell
No Relationships to Disclose